Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bacillus Bacteria
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Destiny Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SPOR COV product consists of a proprietary formulation of Bacillus bacteria that is administered nasally as a spray. It is being developed for for COVID-19 and Influenza.
Brand Name : SPOR-COV
Molecule Type : Vaccine
Upfront Cash : Not Applicable
May 02, 2023
Lead Product(s) : Bacillus Bacteria
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Destiny Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SPOR-COV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Destiny Pharma
Deal Size : $1.0 million
Deal Type : Collaboration
Details : Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.
Brand Name : SPOR-COV
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 08, 2020
Lead Product(s) : SPOR-COV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Destiny Pharma
Deal Size : $1.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
